Bridgeway Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Bridgeway Capital Management’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,400	Closed	-$69.7K	–	1415
2023 Q2	$69.7K	Hold	8,400	–	–	﹤0.01%	1304
2023 Q1	$37K	Hold	8,400	–	–	﹤0.01%	1333
2022 Q4	$49.6K	Hold	8,400	–	–	﹤0.01%	1296
2022 Q3	$59K	Hold	8,400	–	–	﹤0.01%	1338
2022 Q2	$122K	Buy	+8,400	New	+$176K	﹤0.01%	1193

Other funds holding SABS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

PFO

Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

IFAM

Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bridgeway Capital Management's SABS Position: Q3 2023 in Review

Bridgeway Capital Management sold out of SAB Biotherapeutics (SABS) in Q3 2023, closing a stake of 8,400 shares — an estimated $69.7K sold.

Bridgeway Capital Management first reported a position in SABS in Q2 2022 and held it in 5 quarters. The position peaked at $122K in Q2 2022. 34 funds tracked by Wall St. Rank hold SABS as of Q3 2023.

Bridgeway Capital Management reported no remaining SAB Biotherapeutics position as of Q3 2023 after selling out during the quarter.
Bridgeway Capital Management sold 8,400 SAB Biotherapeutics shares in Q3 2023, an estimated $69.7K.
Bridgeway Capital Management first reported a position in SAB Biotherapeutics in Q2 2022 and held it in 5 quarters.
Bridgeway Capital Management's SAB Biotherapeutics position peaked at $122K in Q2 2022.
34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2023.

Based on Bridgeway Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.